surmount-1 trial tirzepatide weight loss non-diabetic π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers Tirzepatide Was Associated with Improved
Pay in 4 interest-free payments of $6.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 5 - Sep 10

























